Insights

The burgeoning telepsychiatry space faces rapidly evolving regulatory and competitive dynamics.  Marwood Group’s Mark Slomiany examines the market landscape and policy considerations in this behavioral health subsector as the public health emergency draws to an end.

Independent community pharmacies, once written off, are benefiting from the tailwinds of a post-big box store era. Herein, Marwood’s Mark Slomiany elaborates on how the current landscape benefits nimble independent community pharmacies that not only achieve cost control but diversify their services.

The recent spike in inflation has yet to fully percolate through the healthcare value chain. Marwood’s Mark Slomiany provides perspective on payor and provider measures and countermeasures likely to accelerate trends reshaping the industry.

In part two of Marwood’s CDMO outlook, Mark Slomiany and Tim Read explore the role CDMOs have played in supporting the pharmaceutical sector, as well as core areas inflecting growth, the evolving M&A landscape, and regulatory considerations.

Rapid innovation in the MedTech sector has original equipment manufacturers seeking CDMO partners that can provide operational efficiencies, specialized expertise, and enhanced quality to support device development and commercialization. Marwood reviews the core services and regulatory considerations that are driving changes in the sector.

When it comes to mitigating compliance risk and audits, providers may actually draw greater risk to themselves by undercoding. Herein, Marwood reviews the risks of performing fraud and abuse by undercoding, the financial impact that it has on healthcare organizations, and actionable steps to mitigate future risk.

“White bagging” is increasingly being utilized by insurers to control provider-administered drug spend. Herein, Marwood presents payor strategies and patient/provider pushback to its implementation.